IPP Bureau
AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer
By IPP Bureau - February 05, 2026
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
FDA reviews AstraZeneca’s Saphnelo for subcutaneous use in Lupus
By IPP Bureau - February 05, 2026
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
GPT Healthcare reports 12% revenue growth in 9M FY26, strengthens clinical capabilities
By IPP Bureau - February 04, 2026
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Sanofi’s Venglustat shows breakthrough results in rare neurological Gaucher disease
By IPP Bureau - February 04, 2026
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
FDA launches PreCheck program to bring drug manufacturing back to US
By IPP Bureau - February 04, 2026
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
Richter’s FYLREVY to transform menopause care in Europe?
By IPP Bureau - February 04, 2026
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
ALX Oncology’s evorpacept shows promise in HER2-positive breast cancer
By IPP Bureau - February 04, 2026
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
Siemens Healthineers launches €10 million R&D hub in Swords, Ireland
By IPP Bureau - February 04, 2026
The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders
_Limited.jpg "Arctic Vision expands global reach with acquisition of MDCO Technology’s ophthalmic device business")
Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy
By IPP Bureau - February 04, 2026
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial
By IPP Bureau - February 04, 2026
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
Cirena launches to revolutionize long RNA production for CRISPR & gene editing
By IPP Bureau - February 04, 2026
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
By IPP Bureau - February 04, 2026
The new service delivers end-to-end support, managing every stage of an epigenomics project
China nod to Darolutamide for metastatic hormone-sensitive prostate cancer
By IPP Bureau - February 04, 2026
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
India’s silent oral cancer crisis: Early detection could save thousands
By IPP Bureau - February 04, 2026
